Liberia Profile Updated
The Liberia profile in ClinRegs has been reviewed and updated with the following information:
- Liberia Medicines and Health Products Regulatory Authority (LMHRA)’s clinical trial regulations from 2025 to include revised regulatory fees, approval timelines for pharmaceutical investigational products, and import documentation requirements (Regulatory Fees, Timeline of Review, and Manufacturing & Import)
- LMHRA safety reporting requirements from 2025 (Safety Reporting)
- Clarification throughout the profile on the role of the Atlantic Center for Research and Evaluation Institutional Review Board (ACRE IRB) in ethical review of research involving human participants other than clinical trials
Sources Added During this Update:
(Regulation) Regulations on Pharmacovigilance in Liberia (LibPVReg) (Version No. 001) (May 28, 2025)
Liberia Medicines and Health Products Regulatory Authority
(Guidance) Guidelines on the Pharmacovigilance System, Pharmacovigilance System Master File and Qualified Person Responsible for Pharmacovigilance in Liberia (G-LibPVSys) (Version No. 001) (Effective June 20, 2025)
Liberia Medicines and Health Products Regulatory Authority
Sources Revised During this Update:
(Regulation) Regulations on Clinical Trials in Liberia (LibCTReg) (Version No. 02) (Effective January 31, 2025)
Liberia Medicines and Health Products Regulatory Authority
(Not Available Online) NIAID Communication with Liberia Medicines and Health Products Regulatory Authority (LMHRA) ( February 2026) (LBR-29)
(Not Available Online) NIAID Communication with the Atlantic Center for Research and Evaluation Institutional Review Board (ACRE IRB) (February 2026) (LBR-28)
(Not Available Online) NIAID Communication with the National Research Ethics Board (NREB) (February 2026) (LBR-38)